Thank you, Paul. As Ed mentioned, the 10-K we filed this afternoon with the SEC offers a detailed explanation of our annual financials. I'm just going to provide you with a bit of color on some of the full year as well as quarterly numbers. For the year ended December 31, 2023, Vuzix reported $12.1 million in total revenues as compared to $11.8 million for the prior year. Product sales increased by 2% year-over-year driven by increased smart glasses revenues. Sales of engineering services for the year increased 3% to $1.4 million from $1.3 million. Please note as disclosed in our 10-K, we have a $2.9 million worth of remaining performance obligations over the revenues already recognized under a current waveguide development project. For the three months ended December 31, 2023, Vuzix reported $1.1 million in total revenues versus $2.9 million in the prior year's fourth quarter. The revenue decline was primarily due to reduced unit sales of our M400 smart glasses. Please note, the Q4 2023 revenue total achieved was below the initially indicated amount in early January pursuant to our cost reduction press release update, as one significant customer order had to be moved from when it originally shipped in December 2023 into the 2024 revenue year, due to shipment and delivery issues discovered later during formal closing procedures. For the full year ended December 31, 2023, there was an overall gross loss of $2.6 million as compared to a $1.5 million gross profit for 2022. Included in 2023's cost of sales was a $4.4 million inventory obsolescence reserve, well above the $0.3 million in obsolescence reserves accrued in our 2022 fiscal year. The large additional inventory reserve amount was related to expected surplus component parts and obsolescence in excess of currently planned existing future product builds in 2024 and in early 2025 and all part of our planned transition to expected new smart glass models in 2025. No finished goods have been included in this reserve. As a disposal value of these excess components that will not likely be used in future product models is unknown. A 100% obsolescence provision was accrued. Research and development expenses for 2023 fell 3% to $12.3 million as compared to $12.7 million for the 2022 period. The decrease was largely due to a $0.9 million reduction in external development and consulting expenses, partially offset by an increase in salary and benefits related expenses and a $0.4 million accrual for severance related costs for staff reductions, which took place in early January 2024. Sales and marketing costs for all of 2023 rose 57% to $12.7 million from $8.1 million in 2022, with the most significant factors being a $2.1 million increase in salary, commissions and benefits related expenses, driven by headcount increases, at $0.4 million provision for staff reductions in this area, which took place in early January 2024, and an increased bad debt reserve allowance of $1.6 million and a $0.6 million increase in advertising and trade show expenses. General and administrative expenses for 2023 decreased 12% to $18.6 million, as compared to $21 million for the 2022 period. The decrease was largely due to a $2.5 million decrease in non-cash, stock-based compensation, primarily related to the company's 2021 long-term incentive plan. For the full year ended December 31st, 2023, the net loss was $50.1 million or $0.79 per share as compared to a loss of $40.8 million or $0.64 per share for the full year of 2022. Now for some balance sheet highlights. Our cash position as of December 31st, 2023 was $26.6 million and we had a net working capital position of $36.3 million. Net cash flows used in operating activities was $26.3 million for the year ended December 31st, 2023, as compared to $24.5 million for the 2022 year, an increase of $1.8 million. Cash used for investing activities in 2023 was $19.3 million down from $21.2 million in 2022. Both of these amounts are well above our historical average for investments. The most significant components of this total investment were $10.5 million in cash payments on further technology development payments pursuant to our exclusive microLED technology license agreement with Atomistic and a $2.5 million investment in the preferred shares of Atomistic purchased from its founders and $5.3 million for purchases of manufacturing equipment and leasehold improvements expenditures, primarily related to our waveguide plant expansion project. We are presently envisioning spending significantly less on investments in 2024 as our new and expanded waveguide manufacturing facility was completed in late 2023. Looking forward to the balance of 2024. We are addressing certain operational challenges highlighted as follows: reducing our operating costs by further operating cost reductions and headcount phrases to better right size our costs in relation to our planned revenues, delay or curtail discretionary and non-essential capital expenditures not related to near-term new products and R&D. As mentioned in our 10-K filing, the probable implementation of a voluntary cash, salary reduction program in exchange for equity instruments offered to all salaried employees and management. We are also actively pursuing licensing and strategic opportunities around waveguide technologies with potential OEMs, which include the receipt of upfront licensing fees and ongoing supply agreements. As Paul mentioned, some potential strategic investments. As most of you are aware, we are in the process of going effective with our new S-3 shelf registration statement with the SEC as Vuzix has found it prudent to have one in place over the past many years. The new SR includes a provision for an ATM or at-the-market offering with an investment banking firm to raise capital on the best terms if favorable market conditions develop. And as pointed out in our recent 10-K, there is a cautionary going concern note to our financial statements that projecting our cash needs out over the next 12 months, there is possible financial uncertainty related to the full alleviation of all our current going concern risk. Vuzix's management is confident based on its plan and history of managing his operations and successful capital raises over the past 2 decades that it can fully alleviate those financial risks over the next 12 months. As a result, our financial statements have been prepared on a going concern basis. This presentation assumes that the company will continue normal business operations into the future. However, as noted in our 10-K, the company's external auditors do not share the opinion that such financial risks are yet fully alleviated and have included a cautionary note in that regard in their audit report. This is an opinion that management does not agree with. And before concluding, we would like to apologize to our stockholders for having to take advantage of the 15-day grace period for the filing of our 10-K for 2023 with the SEC. As it should be evident to most, there were a variety of issues, assumptions and extra efforts required to properly prepare our financial statements and complete our external audit to the satisfaction of all relevant parties. We expect this delay will not be repeated again in the near future. With that, I would like to turn the call back over to Paul.